warfarin

(redirected from warfarin sodium)
Also found in: Dictionary, Thesaurus, Medical.
Related to warfarin sodium: digoxin

warfarin

(wôr`fərĭn), anticoagulantanticoagulant
, any of several substances that inhibit blood clot formation (see blood clotting). Some anticoagulants, such as the coumarin derivatives bishydroxycoumarin (Dicumarol) and warfarin (Coumadin) inhibit synthesis of prothrombin, a clot-forming substance, and other
..... Click the link for more information.
 used to treat blood clots. In large doses it causes bleeding, and in patients with genetic variations that increase sensitivity to the drug and decrease the rate at which it is metabolized standard dosages may also cause bleeding. Warfarin, mixed with bait, is used in rodent control.
References in periodicals archive ?
Furthermore, in issuing a bold relabeling of warfarin sodium in 2007, the Food and Drug Administration recommended the use of currently available (and quite predictive) genetic testing to help guide initial dosing of this anticoagulant to reduce the risk of catastrophic hemorrhage (5).
Innohep(R) is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin(R)) in hospitalized patients.
Tenders are invited for Warfarin Sodium 5 Mg Tab Each Strip Containing 10 Tabs
They are typically put on lifelong oral anticoagulation therapy with warfarin sodium (e.
Hart and the GLRS Antitrust Litigation team recently won settlements in the In Re Warfarin Sodium Antitrust Litigation against DuPont Pharmaceuticals.
The Company currently markets Warfarin Sodium Tablets and Acetazolamide Tablets, in addition to the more recent approvals for Amiodarone Hydrochloride Tablets, Enalapril Maleate Tablets and Enalapril/HCTZ.
The RE-LY trial is comparing two blinded doses of oral dabigatran etexilate with warfarin sodium (target INR 2.
Taro also markets Acetazolamide Tablets and Warfarin Sodium Tablets in all nine strengths, products which are indicated for cardiovascular diseases.
market share of oral prescription products such as carbamazepine tablets, bioequivalent to Novartis' Tegretol(R), and warfarin sodium tablets, bioequivalent to Dupont's Coumadin(R).
0 Million in Q3 1999 -- Gross Profit Increases 33% -- 19th Consecutive Quarter of Record Sales, 8th Consecutive Quarter of Record Net Income -- Taro Granted Additional Patent for Non-Sedating Barbiturates in Q3 -- Taro's Warfarin Sodium Tablets Approved in Canada in Q3

Full browser ?